Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $38.0 million.

  • Krystal Biotech's Free Cash Flow fell 3581.42% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.2 million, marking a year-over-year increase of 20572.51%. This contributed to the annual value of $114.9 million for FY2024, which is 21423.42% up from last year.
  • Per Krystal Biotech's latest filing, its Free Cash Flow stood at $38.0 million for Q3 2025, which was down 3581.42% from $50.8 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Free Cash Flow registered a high of $59.1 million during Q3 2024, and its lowest value of -$61.8 million during Q4 2021.
  • Over the past 5 years, Krystal Biotech's median Free Cash Flow value was -$17.7 million (recorded in 2021), while the average stood at -$7.5 million.
  • In the last 5 years, Krystal Biotech's Free Cash Flow tumbled by 23739.59% in 2022 and then soared by 128750.0% in 2025.
  • Krystal Biotech's Free Cash Flow (Quarter) stood at -$61.8 million in 2021, then surged by 55.41% to -$27.5 million in 2022, then skyrocketed by 71.22% to -$7.9 million in 2023, then skyrocketed by 763.95% to $52.6 million in 2024, then decreased by 27.89% to $38.0 million in 2025.
  • Its last three reported values are $38.0 million in Q3 2025, $50.8 million for Q2 2025, and $24.8 million during Q1 2025.